Literature DB >> 661315

A radioimmunoassay for serum medroxyprogesterone acetate.

K Shrimanker, B N Saxena, K Fotherby.   

Abstract

Entities:  

Keywords:  Animals, Laboratory; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Depo-provera; Family Planning; Injectables; Medroxyprogesterone Acetate; Research Methodology

Mesh：

Substances：

Year:  1978        PMID： 661315     DOI： 10.1016/0022-4731(78)90631-3

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN： 0022-4731            Impact factor:   4.292


× No keyword cloud information.
  17 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

2.  Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.

Authors:  S Lundgren; P E Lønning; A Aakvaag; S Kvinnsland
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs.

Authors:  Richard P H Huijbregts; Katherine G Michel; Zdenek Hel
Journal:  Contraception       Date:  2014-02-26       Impact factor: 3.375

4.  Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms.

Authors:  Richard P H Huijbregts; E Scott Helton; Katherine G Michel; Steffanie Sabbaj; Holly E Richter; Paul A Goepfert; Zdenek Hel
Journal:  Endocrinology       Date:  2013-01-25       Impact factor: 4.736

Review 5.  Long acting contraceptives. Present status.

Authors:  G Benagiano; F M Primiero
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

6.  Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.

Authors:  C M Camaggi; E Strocchi; M Giovannini; B Angelelli; B Costanti; E Zebini; P Ferrari; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

7.  Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.

Authors:  D W Hedley; M Christie; R P Weatherby; I D Caterson
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?

Authors:  Chelsea B Polis; Sharon L Achilles; Zdenek Hel; Janet P Hapgood
Journal:  Contraception       Date:  2017-12-11       Impact factor: 3.375

9.  Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection.

Authors:  Rodolfo D Vicetti Miguel; Robert L Hendricks; Alfredo J Aguirre; Melissa A Melan; Stephen A K Harvey; Tracy Terry-Allison; Anthony J St Leger; Angus W Thomson; Thomas L Cherpes
Journal:  J Immunol       Date:  2012-08-31       Impact factor: 5.422

10.  Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies.

Authors:  M Izuo; Y Iino; K Endo
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.